Clay Siegall is the CEO and also chairman of the board at Seattle genetics. Siegall started the genetics company way back in the year 1998 and ever since he has been on the verge of coming up with special treatment drugs to counter several ailments related to cancer. Some of the drugs include Adcetris which is the company’s flagship drug. The drug is expected to treat the Hodgkin Lymphoma which is a cancer of the Lymph system.
Currently, the company boasts of having a market value of $10 billion dollars and a roaster of 900 employees. This alone makes it the leading biotech company in Washington. Siegall goes on to state that they are an emerging global multi-product oncology company that is on the staircase to be a global player. Siegall is a sign of commitment to this global market made a bid to spend $2 billion to commercialize a cancer drug that had been developed by the New Jersey Immuno medics. This could not be possible later on because a judge ruled out any possibilities of it happening since there was a struggle for power in the immunomedics board.
Seattle genetics sales trajectory is a forward trajectory though the company is yet to make some profit after 18 years. This could be changed with the company focusing on eleven drug types. Siegal confirms that their focus is on four of the drug types them including the Adcetris that was approved by the Food and Drug Administration (FDA). The drug is expected to act as a complement to the treatment of the Hodgkin lymphoma. The drug is on a trajectory to raise close to a billion dollars. The other drugs include number 33A poised to counter acute myeloid leukemia or the AML, and finally, 22ME that is aimed at bladder cancer.
Clays’ place in the spotlight has been possible because of the steadfast progress against cancer. He goes on to say that he loves making drugs but also admits that it is a path full of ups and downs.
Clay Siegall is the founder, president, CEO and also chairman at Seattle genetics. Under his leadership, the company has grown to build a diverse pipeline in the counter against cancer.
Before founding Seattle genetics, Siegall was with the Bristol-Myers Squibb Pharmaceutical Research Institute in the years between 1991 and 1997. Other companies that he has worked with include: National Cancer Institute and also National Institutes of Health.
Siegall has a B.S in zoology from the University of Maryland and also a Ph. D in genetics from Washington University.